BioNTech and OncoC4 report updated gotistobart OS data
The companies said updated results from PRESERVE-003 stage 1 show gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients, and they announced first median OS data from stage 1.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.